Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report.

ABSTRACT: •Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.

SUBMITTER: Paspalj V 

PROVIDER: S-EPMC8253948 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature